» Articles » PMID: 26042650

Influenza Activity - United States, 2014-15 Season and Composition of the 2015-16 Influenza Vaccine

Abstract

During the 2014-15 influenza season in the United States, influenza activity increased through late November and December before peaking in late December. Influenza A (H3N2) viruses predominated, and the prevalence of influenza B viruses increased late in the season. This influenza season, similar to previous influenza A (H3N2)-predominant seasons, was moderately severe with overall high levels of outpatient illness and influenza-associated hospitalization, especially for adults aged ≥65 years. The majority of circulating influenza A (H3N2) viruses were different from the influenza A (H3N2) component of the 2014-15 Northern Hemisphere seasonal vaccines, and the predominance of these drifted viruses resulted in reduced vaccine effectiveness. This report summarizes influenza activity in the United States during the 2014-15 influenza season (September 28, 2014-May 23, 2015) and reports the recommendations for the components of the 2015-16 Northern Hemisphere influenza vaccine.

Citing Articles

Structural mapping of polyclonal IgG responses to HA after influenza virus vaccination or infection.

Leon A, Rodriguez A, Richey S, Torrents de la Pena A, Wolters R, Jackson A mBio. 2025; 16(3):e0203024.

PMID: 39912630 PMC: 11898601. DOI: 10.1128/mbio.02030-24.


The Relationship between Immunogenicity and Reactogenicity of Seasonal Influenza Vaccine Using Different Delivery Methods.

Gromer D, Plikaytis B, McCullough M, Wimalasena S, Rouphael N Vaccines (Basel). 2024; 12(7).

PMID: 39066447 PMC: 11281354. DOI: 10.3390/vaccines12070809.


Structural Mapping of Polyclonal IgG Responses to HA After Influenza Virus Vaccination or Infection.

Leon A, Rodriguez A, Richey S, Torrents de la Pena A, Wolters R, Jackson A bioRxiv. 2024; .

PMID: 39026813 PMC: 11257458. DOI: 10.1101/2024.07.08.601940.


Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines.

Russell C, Fouchier R, Ghaswalla P, Park Y, Vicic N, Ananworanich J Hum Vaccin Immunother. 2024; 20(1):2336357.

PMID: 38619079 PMC: 11020595. DOI: 10.1080/21645515.2024.2336357.


New Vaccine Platforms-Novel Dimensions of Economic and Societal Value and Their Measurement.

Buck P, Gomes D, Beck E, Kirson N, Mattera M, Carroll S Vaccines (Basel). 2024; 12(3).

PMID: 38543868 PMC: 10974797. DOI: 10.3390/vaccines12030234.


References
1.
Rolfes M, Blanton L, Brammer L, Smith S, Mustaquim D, Steffens C . Update: influenza activity - United States, September 28- December 6, 2014. MMWR Morb Mortal Wkly Rep. 2014; 63(50):1189-94. PMC: 5779524. View

2.
. Estimates of deaths associated with seasonal influenza --- United States, 1976-2007. MMWR Morb Mortal Wkly Rep. 2010; 59(33):1057-62. View

3.
Flannery B, Clippard J, Zimmerman R, Nowalk M, Jackson M, Jackson L . Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb Mortal Wkly Rep. 2015; 64(1):10-5. PMC: 4584793. View

4.
Thompson W, Shay D, Weintraub E, Brammer L, Bridges C, Cox N . Influenza-associated hospitalizations in the United States. JAMA. 2004; 292(11):1333-40. DOI: 10.1001/jama.292.11.1333. View

5.
Fiore A, Fry A, Shay D, Gubareva L, Bresee J, Uyeki T . Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011; 60(1):1-24. View